Catabasis Pharmaceuticals Announces Proposed Underwritten Public Offering
BOSTON--(BUSINESS WIRE)--Jan 29, 2020--
Catabasis Pharmaceuticals, Inc. (“Catabasis,” the “Company,” “we,” “our,” or “us”) (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it intends to offer its securities in an underwritten public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Oppenheimer & Co. Inc. is acting as sole underwriter for the offering.
Catabasis intends to use the net proceeds from the offering for clinical trial and other research and development activities; initial commercialization preparations; and for working capital and other general corporate purposes.
The securities described above will be offered pursuant to a shelf registration statement on Form S-3 (No. 333-231441), which was previously filed with and declared effective by the Securities and Exchange Commission (“SEC”) on May 23, 2019. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov, copies of which may be obtained, when available, from Oppenheimer & Co. Inc. Attention: Syndicate Prospectus Department, 85 Broad St., 26th Floor, New York, NY 10004, by telephone at (212) 667-8055 or by email at EquityProspectus@opco.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in Phase 3 development for the treatment of Duchenne muscular dystrophy.
Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the anticipated public offering and the anticipated use of net proceeds therefrom, among other things, statements containing the words “believes,” “anticipates,” “plans,” “expects,” “may” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: market conditions that may affect the timing, terms and conditions of the offering, the Company’s ability to satisfy the conditions to closing of the offering and other matters affecting our ability to consummate the offering on terms acceptable to us. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this release.
View source version on businesswire.com:https://www.businesswire.com/news/home/20200129005689/en/
CONTACT: Investor and Media Contact
Catabasis Pharmaceuticals, Inc.
T: (617) 349-1971
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH CLINICAL TRIALS
SOURCE: Catabasis Pharmaceuticals, Inc.
Copyright Business Wire 2020.
PUB: 01/29/2020 04:01 PM/DISC: 01/29/2020 04:04 PM